LEMAITRE VASCULAR INC (LMAT) Fundamental Analysis & Valuation

NASDAQ:LMAT • US5255582018

108.34 USD
-0.86 (-0.79%)
At close: Mar 11, 2026
108.34 USD
0 (0%)
After Hours: 3/11/2026, 5:20:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This LMAT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

Taking everything into account, LMAT scores 7 out of 10 in our fundamental rating. LMAT was compared to 184 industry peers in the Health Care Equipment & Supplies industry. LMAT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. LMAT has a decent growth rate and is not valued too expensively. This makes LMAT very considerable for quality investing!


Dividend Valuation Growth Profitability Health

9

1. LMAT Profitability Analysis

1.1 Basic Checks

  • LMAT had positive earnings in the past year.
  • LMAT had a positive operating cash flow in the past year.
  • LMAT had positive earnings in each of the past 5 years.
  • LMAT had a positive operating cash flow in each of the past 5 years.
LMAT Yearly Net Income VS EBIT VS OCF VS FCFLMAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

1.2 Ratios

  • LMAT has a better Return On Assets (9.38%) than 89.13% of its industry peers.
  • LMAT has a Return On Equity of 14.67%. This is amongst the best in the industry. LMAT outperforms 89.67% of its industry peers.
  • The Return On Invested Capital of LMAT (9.04%) is better than 86.96% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for LMAT is in line with the industry average of 9.15%.
  • The last Return On Invested Capital (9.04%) for LMAT is above the 3 year average (8.61%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.38%
ROE 14.67%
ROIC 9.04%
ROA(3y)8.68%
ROA(5y)8.37%
ROE(3y)12.61%
ROE(5y)11.22%
ROIC(3y)8.61%
ROIC(5y)8.85%
LMAT Yearly ROA, ROE, ROICLMAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • LMAT has a Profit Margin of 23.13%. This is amongst the best in the industry. LMAT outperforms 95.11% of its industry peers.
  • LMAT's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 27.21%, LMAT belongs to the best of the industry, outperforming 96.20% of the companies in the same industry.
  • LMAT's Operating Margin has improved in the last couple of years.
  • LMAT has a better Gross Margin (71.53%) than 80.43% of its industry peers.
  • In the last couple of years the Gross Margin of LMAT has grown nicely.
Industry RankSector Rank
OM 27.21%
PM (TTM) 23.13%
GM 71.53%
OM growth 3Y13.74%
OM growth 5Y4.46%
PM growth 3Y22%
PM growth 5Y7.14%
GM growth 3Y3.31%
GM growth 5Y1.81%
LMAT Yearly Profit, Operating, Gross MarginsLMAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. LMAT Health Analysis

2.1 Basic Checks

  • LMAT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, LMAT has more shares outstanding
  • LMAT has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for LMAT has been reduced compared to a year ago.
LMAT Yearly Shares OutstandingLMAT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
LMAT Yearly Total Debt VS Total AssetsLMAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 8.75 indicates that LMAT is not in any danger for bankruptcy at the moment.
  • LMAT has a Altman-Z score of 8.75. This is amongst the best in the industry. LMAT outperforms 88.04% of its industry peers.
  • The Debt to FCF ratio of LMAT is 2.26, which is a good value as it means it would take LMAT, 2.26 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of LMAT (2.26) is better than 85.87% of its industry peers.
  • LMAT has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of LMAT (0.43) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF 2.26
Altman-Z 8.75
ROIC/WACC0.92
WACC9.79%
LMAT Yearly LT Debt VS Equity VS FCFLMAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 12.89 indicates that LMAT has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 12.89, LMAT belongs to the top of the industry, outperforming 97.28% of the companies in the same industry.
  • A Quick Ratio of 10.95 indicates that LMAT has no problem at all paying its short term obligations.
  • LMAT's Quick ratio of 10.95 is amongst the best of the industry. LMAT outperforms 96.74% of its industry peers.
Industry RankSector Rank
Current Ratio 12.89
Quick Ratio 10.95
LMAT Yearly Current Assets VS Current LiabilitesLMAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. LMAT Growth Analysis

3.1 Past

  • LMAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.68%, which is quite impressive.
  • LMAT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 17.12% yearly.
  • LMAT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.53%.
  • The Revenue has been growing by 14.04% on average over the past years. This is quite good.
EPS 1Y (TTM)22.68%
EPS 3Y36.78%
EPS 5Y17.12%
EPS Q2Q%38.78%
Revenue 1Y (TTM)13.53%
Revenue growth 3Y15.57%
Revenue growth 5Y14.04%
Sales Q2Q%15.68%

3.2 Future

  • Based on estimates for the next years, LMAT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.37% on average per year.
  • The Revenue is expected to grow by 9.67% on average over the next years. This is quite good.
EPS Next Y20.86%
EPS Next 2Y15.35%
EPS Next 3Y12.89%
EPS Next 5Y11.37%
Revenue Next Year12.16%
Revenue Next 2Y10.55%
Revenue Next 3Y10.08%
Revenue Next 5Y9.67%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LMAT Yearly Revenue VS EstimatesLMAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
LMAT Yearly EPS VS EstimatesLMAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

4

4. LMAT Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 45.52, the valuation of LMAT can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of LMAT indicates a somewhat cheap valuation: LMAT is cheaper than 68.48% of the companies listed in the same industry.
  • LMAT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.15.
  • A Price/Forward Earnings ratio of 37.67 indicates a quite expensive valuation of LMAT.
  • Based on the Price/Forward Earnings ratio, LMAT is valued a bit cheaper than the industry average as 69.02% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 24.27. LMAT is valued rather expensively when compared to this.
Industry RankSector Rank
PE 45.52
Fwd PE 37.67
LMAT Price Earnings VS Forward Price EarningsLMAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • LMAT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LMAT is cheaper than 71.74% of the companies in the same industry.
  • 77.72% of the companies in the same industry are more expensive than LMAT, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 33.14
EV/EBITDA 25.1
LMAT Per share dataLMAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates LMAT does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of LMAT may justify a higher PE ratio.
  • A more expensive valuation may be justified as LMAT's earnings are expected to grow with 12.89% in the coming years.
PEG (NY)2.18
PEG (5Y)2.66
EPS Next 2Y15.35%
EPS Next 3Y12.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. LMAT Dividend Analysis

5.1 Amount

  • LMAT has a yearly dividend return of 0.94%, which is pretty low.
  • LMAT's Dividend Yield is rather good when compared to the industry average which is at 0.21. LMAT pays more dividend than 92.39% of the companies in the same industry.
  • With a Dividend Yield of 0.94, LMAT pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.94%

5.2 History

  • On average, the dividend of LMAT grows each year by 16.13%, which is quite nice.
  • LMAT has been paying a dividend for at least 10 years, so it has a reliable track record.
  • LMAT has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)16.13%
Div Incr Years13
Div Non Decr Years13
LMAT Yearly Dividends per shareLMAT Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • 31.37% of the earnings are spent on dividend by LMAT. This is a low number and sustainable payout ratio.
  • The dividend of LMAT is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP31.37%
EPS Next 2Y15.35%
EPS Next 3Y12.89%
LMAT Yearly Income VS Free CF VS DividendLMAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
LMAT Dividend Payout.LMAT Dividend Payout, showing the Payout Ratio.LMAT Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

LMAT Fundamentals: All Metrics, Ratios and Statistics

LEMAITRE VASCULAR INC

NASDAQ:LMAT (3/11/2026, 5:20:01 PM)

After market: 108.34 0 (0%)

108.34

-0.86 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners96.24%
Inst Owner Change7.54%
Ins Owners7.97%
Ins Owner Change-9.74%
Market Cap2.47B
Revenue(TTM)249.60M
Net Income(TTM)57.73M
Analysts78.82
Price Target105.74 (-2.4%)
Short Float %5.63%
Short Ratio6.31
Dividend
Industry RankSector Rank
Dividend Yield 0.94%
Yearly Dividend0.8
Dividend Growth(5Y)16.13%
DP31.37%
Div Incr Years13
Div Non Decr Years13
Ex-Date03-12
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.9%
Min EPS beat(2)0.42%
Max EPS beat(2)7.38%
EPS beat(4)3
Avg EPS beat(4)1.52%
Min EPS beat(4)-5.52%
Max EPS beat(4)7.38%
EPS beat(8)6
Avg EPS beat(8)4.19%
EPS beat(12)10
Avg EPS beat(12)5.13%
EPS beat(16)10
Avg EPS beat(16)-0.04%
Revenue beat(2)1
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-3.74%
Max Revenue beat(2)0.58%
Revenue beat(4)3
Avg Revenue beat(4)-0.13%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.83%
Revenue beat(8)5
Avg Revenue beat(8)-0.14%
Revenue beat(12)7
Avg Revenue beat(12)0.21%
Revenue beat(16)8
Avg Revenue beat(16)-0.25%
PT rev (1m)0%
PT rev (3m)-0.64%
EPS NQ rev (1m)6.8%
EPS NQ rev (3m)6.8%
EPS NY rev (1m)9.01%
EPS NY rev (3m)9.01%
Revenue NQ rev (1m)1.08%
Revenue NQ rev (3m)1.08%
Revenue NY rev (1m)2.72%
Revenue NY rev (3m)2.72%
Valuation
Industry RankSector Rank
PE 45.52
Fwd PE 37.67
P/S 9.89
P/FCF 33.14
P/OCF 30.37
P/B 6.27
P/tB 8.38
EV/EBITDA 25.1
EPS(TTM)2.38
EY2.2%
EPS(NY)2.88
Fwd EY2.65%
FCF(TTM)3.27
FCFY3.02%
OCF(TTM)3.57
OCFY3.29%
SpS10.96
BVpS17.27
TBVpS12.93
PEG (NY)2.18
PEG (5Y)2.66
Graham Number30.41
Profitability
Industry RankSector Rank
ROA 9.38%
ROE 14.67%
ROCE 11.72%
ROIC 9.04%
ROICexc 23.78%
ROICexgc 43.2%
OM 27.21%
PM (TTM) 23.13%
GM 71.53%
FCFM 29.83%
ROA(3y)8.68%
ROA(5y)8.37%
ROE(3y)12.61%
ROE(5y)11.22%
ROIC(3y)8.61%
ROIC(5y)8.85%
ROICexc(3y)18.5%
ROICexc(5y)16.17%
ROICexgc(3y)34.8%
ROICexgc(5y)32.81%
ROCE(3y)11.16%
ROCE(5y)11.48%
ROICexgc growth 3Y19.07%
ROICexgc growth 5Y8.49%
ROICexc growth 3Y27.82%
ROICexc growth 5Y16.94%
OM growth 3Y13.74%
OM growth 5Y4.46%
PM growth 3Y22%
PM growth 5Y7.14%
GM growth 3Y3.31%
GM growth 5Y1.81%
F-Score7
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF 2.26
Debt/EBITDA 2.15
Cap/Depr 65.11%
Cap/Sales 2.72%
Interest Coverage 250
Cash Conversion 103.73%
Profit Quality 128.99%
Current Ratio 12.89
Quick Ratio 10.95
Altman-Z 8.75
F-Score7
WACC9.79%
ROIC/WACC0.92
Cap/Depr(3y)71.15%
Cap/Depr(5y)58.36%
Cap/Sales(3y)3.21%
Cap/Sales(5y)2.96%
Profit Quality(3y)103.77%
Profit Quality(5y)106.24%
High Growth Momentum
Growth
EPS 1Y (TTM)22.68%
EPS 3Y36.78%
EPS 5Y17.12%
EPS Q2Q%38.78%
EPS Next Y20.86%
EPS Next 2Y15.35%
EPS Next 3Y12.89%
EPS Next 5Y11.37%
Revenue 1Y (TTM)13.53%
Revenue growth 3Y15.57%
Revenue growth 5Y14.04%
Sales Q2Q%15.68%
Revenue Next Year12.16%
Revenue Next 2Y10.55%
Revenue Next 3Y10.08%
Revenue Next 5Y9.67%
EBIT growth 1Y29.96%
EBIT growth 3Y31.45%
EBIT growth 5Y19.13%
EBIT Next Year38.55%
EBIT Next 3Y19.89%
EBIT Next 5Y16.94%
FCF growth 1Y100.39%
FCF growth 3Y49.81%
FCF growth 5Y18.54%
OCF growth 1Y84.14%
OCF growth 3Y47.38%
OCF growth 5Y18.48%

LEMAITRE VASCULAR INC / LMAT FAQ

What is the ChartMill fundamental rating of LEMAITRE VASCULAR INC (LMAT) stock?

ChartMill assigns a fundamental rating of 7 / 10 to LMAT.


What is the valuation status of LEMAITRE VASCULAR INC (LMAT) stock?

ChartMill assigns a valuation rating of 4 / 10 to LEMAITRE VASCULAR INC (LMAT). This can be considered as Fairly Valued.


How profitable is LEMAITRE VASCULAR INC (LMAT) stock?

LEMAITRE VASCULAR INC (LMAT) has a profitability rating of 9 / 10.


What is the valuation of LEMAITRE VASCULAR INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for LEMAITRE VASCULAR INC (LMAT) is 45.52 and the Price/Book (PB) ratio is 6.27.


How financially healthy is LEMAITRE VASCULAR INC?

The financial health rating of LEMAITRE VASCULAR INC (LMAT) is 8 / 10.